Orchestra BioMed Holdings Inc. (OBIO) - Total Liabilities
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has total liabilities worth $49.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Orchestra BioMed Holdings Inc. to track the company's year-over-year net asset growth rate.
Orchestra BioMed Holdings Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Orchestra BioMed Holdings Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Orchestra BioMed Holdings Inc. Competitors by Total Liabilities
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Union Insurance Co Ltd
TW:2816
|
Taiwan | NT$12.06 Billion |
|
Ritek Corp
TW:2349
|
Taiwan | NT$8.30 Billion |
|
LTC Co.Ltd
KQ:170920
|
Korea | ₩159.65 Billion |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
India | Rs13.38 Billion |
|
Y.U.D. Yangtze River Investment Industry Co Ltd
SHG:600119
|
China | CN¥275.07 Million |
|
Jasuindo Tiga Perkasa Tbk
JK:JTPE
|
Indonesia | Rp768.02 Billion |
|
EPACK Durable Limited
NSE:EPACK
|
India | Rs10.59 Billion |
|
DFI Inc
TW:2397
|
Taiwan | NT$6.65 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Orchestra BioMed Holdings Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OBIO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orchestra BioMed Holdings Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual total liabilities of Orchestra BioMed Holdings Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $51.48 Million | +19.12% |
| 2024-12-31 | $43.22 Million | +59.06% |
| 2023-12-31 | $27.17 Million | -36.87% |
| 2022-12-31 | $43.04 Million | -49.22% |
| 2021-12-31 | $84.76 Million | -2.16% |
| 2020-12-31 | $86.63 Million | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more